EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy

Andreas Halman iD, Rachel Conyers iD, Claire Moore iD, Dhrita Khatri iD, Jerome Sarris, Daniel Perkins iD

Clinical Pharmacology & Therapeutics · 2025-01 · 117 (1) · 106-115

DOI: 10.1002/cpt.3459 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.09.2024. Verfasst von Andreas Halman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Psychae Therapeutics, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Hallucinogens, Pharmacogenetics, Precision Medicine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics to explore the utility of pharmacogenomics (a key component of personalized medicine) in psychedelic‐assisted therapies. We summarized the literature and explored the potential implications of genetic variability on the pharmacodynamics and pharmacokinetics of psychedelic drugs including lysergic acid diethylamide (LSD), psilocybin, N,N ‐dimethyltryptamine (DMT), 5‐methoxy‐ N,N ‐dimethyltryptamine (5‐MeO‐DMT), ibogaine and 3,4‐methylenedioxymethamphetamine (MDMA). Although existing evidence is limited, particularly concerning pharmacodynamics, studies investigating pharmacokinetics indicate that genetic variants in drug‐metabolizing enzymes, such as cytochrome P450, impact the intensity of acute psychedelic effects for LSD and ibogaine, and that a dose reduction for CYP2D6 poor metabolizers may be appropriate. Furthermore, based on the preclinical evidence, it can be hypothesized that CYP2D6 metabolizer status might contribute to altered acute psychedelic experiences with 5‐MeO‐DMT and psilocybin when combined with monoamine oxidase inhibitors. In conclusion, considering early evidence that genetic factors can influence the effects of certain psychedelics, we suggest that pharmacogenomic testing should be further investigated in clinical research. This is necessary to evaluate its utility in improving the safety and therapeutic profile of psychedelic therapies and a potential future role in personalizing psychedelic‐assisted therapies, should these treatments become available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensPharmacogeneticsPrecision MedicineHumansMental Disorders

Substanzen

Hallucinogens

Autor:innen und Institutionen

  • Psychae Therapeutics, Melbourne, Victoria, Australia.
  • Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
  • Centre for Mental Health, Swinburne University, Melbourne, Victoria, Australia.
  • NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia.

ORCID-Profile: Andreas Halman, Rachel Conyers, Claire Moore, Dhrita Khatri, Daniel Perkins

Zitieren

APA

Halman, A., Conyers, R., Moore, C., Khatri, D., Sarris, J., & Perkins, D. (2025). Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy. Clinical Pharmacology & Therapeutics, 117(1), 106-115. https://doi.org/10.1002/cpt.3459

Vancouver

Halman A, Conyers R, Moore C, Khatri D, Sarris J, Perkins D. Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy. Clinical Pharmacology & Therapeutics. 2025;117(1):106-115. doi:10.1002/cpt.3459

BibTeX
@article{Halman2025,
  author = {Halman, Andreas and Conyers, Rachel and Moore, Claire and Khatri, Dhrita and Sarris, Jerome and Perkins, Daniel},
  title = {Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {1},
  pages = {106--115},
  doi = {10.1002/cpt.3459}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche